

## Technology Advisory Committee A Interests Register

### Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer [ID6279]

Publication Date: 13/12/2023

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Becky Pennington	TAC A Committee Member	Indirect - Financial Interests	Beck received consultancy fees from Roche related to methods research on carer HRQL, not related to bevacizumab or this indication.	14/09/2023	N/A	It was agreed that Becky's declaration would not prevent her from providing expert advice to the committee.
Patrick De Barr	TAC A Committee Member	Indirect - Financial Interests	Patrick works for Incyte who are developing a PD1 antibody. However this is in a different lead indication (anal cell carcinoma and merkel cell carcinoma). The phase 1 development will have included multiple tumour types including melanoma. This is standard for development of oncology products.	18/09/2023	N/A	It was agreed that Patrick's declaration would not prevent him from providing expert advice to the committee.

